The fibromyalgia treatment market value across seven major markets (7MM) of the US, France, Germany, Italy, Spain, the UK, and Japan, will rise from $1.8 billion in 2013 at a low Compound Annual Growth Rate (CAGR) of 0.72% to reach $1.9 billion by 2023, according to research and consulting firm GlobalData.
PharmaPoint's latest report 'Global Drug Forecast and Market Analysis to 2023' states that while this growth will be primarily driven by the potential introduction of four late-stage pipeline agents, consisting of reformulations of existing therapies and "me-too" products, it will also be dampened by the simultaneous patent expiries of the key branded products on the market.
Fibromyalgia
Fibromyalgia (FM) is a chronic health condition charecterized by widespread pain and stiffness in the muscles, joints and tendons. It is considered to be a co-morbid disorder.
Advertisement
Maura Musciacco, GlobalData's Director of Neurology and Ophthalmology, says the US will consolidate its position as the dominant market, with the country's share increasing from 83% of fibromyalgia treatment sales in 2013 to 86% by 2023.
Musciacco explains: "The US is the only country among the 7MM with three approved brands: Lyrica, Cymbalta, and Savella. Along with its higher drug prices and prescribing rates, the largest fibromyalgia population, and a greater number of pipeline products compared with the other six countries, the US holds a greater share of the fibromyalgia treatment arena."
![Research Sheds Light on Fibromyalgia and the Role of Brain Connectivity in Pain Inhibition]( "Research Sheds Light on Fibromyalgia and the Role of Brain Connectivity in Pain Inhibition")
Despite extensive research, the cause of fibromyalgia, a chronic pain syndrome is not known.
"The small range of currently available fibromyalgia therapeutics means that the market will welcome new products that can offer patients better efficacy, convenience, and safety. To date, four pipeline agents will potentially be introduced by 2023, mainly in the US."
These products include two reformulations, namely Pfizer's Lyrica CR and Tonix Pharmaceutical's TNX-102 SL, and two "me-too" products, namely Daiichi Sankyo's DS-5655 and Theravance Biopharma's TD-9855.
Musciacco continues: "The estimated cost of these treatments will be comparatively higher than the currently available fibromyalgia therapies and the inexpensive generic products. These higher costs will drive an increase in the overall value of the fibromyalgia market over the forecast period."
"However, Lyrica, Cymbalta, and Savella have already or will experience generic erosion between 2013 and 2023. Generic medicines are likely to dominate sales in countries where the pipeline products are limited or not available, while markets crowded with generics will see limited sales growth for new entrants."
Source: Medindia
Research Sheds Light on Fibromyalgia and the Role of Brain Connectivity in Pain Inhibition
Despite extensive research, the cause of fibromyalgia, a chronic pain syndrome is not known.
Advertisement
"The small range of currently available fibromyalgia therapeutics means that the market will welcome new products that can offer patients better efficacy, convenience, and safety. To date, four pipeline agents will potentially be introduced by 2023, mainly in the US."
These products include two reformulations, namely Pfizer's Lyrica CR and Tonix Pharmaceutical's TNX-102 SL, and two "me-too" products, namely Daiichi Sankyo's DS-5655 and Theravance Biopharma's TD-9855.
Musciacco continues: "The estimated cost of these treatments will be comparatively higher than the currently available fibromyalgia therapies and the inexpensive generic products. These higher costs will drive an increase in the overall value of the fibromyalgia market over the forecast period."
"However, Lyrica, Cymbalta, and Savella have already or will experience generic erosion between 2013 and 2023. Generic medicines are likely to dominate sales in countries where the pipeline products are limited or not available, while markets crowded with generics will see limited sales growth for new entrants."
Source: Medindia
Clinic Study Shows Young People Report Worse Fibromyalgia Than Older Patients
A Mayo Clinic study shows that young and middle-aged fibromyalgia patients report worse symptoms and poorer quality of life than older patients.
Advertisement
 Fibromyalgia Patients can Get Some Relief Through Whole-Body Vibration ExercisePeople suffering from fibromyalgia can benefit by whole-body vibration exercise, which can reduce pain symptoms and improve their quality of life. | Advertisement
|
Advertisement
Recommended Readings
Latest Drug News
Examining FDA and patent records, researchers found that insulin manufacturers prolong market exclusivity for brand-name products.
The rise in FDA ODD awards indicates a collective endeavor to create new myelofibrosis medications devoid of mechanisms inducing anemia.
The most significant decrease in autoimmune thyroid disease risk was observed in rheumatoid arthritis patients receiving immunomodulatory drugs or 'biological DMARDs'.
Human apotransferrin injected to mice models suffering from intracerebral hemorrhage was found to mitigate the serious effects of stroke.
The reduction of these senescent osteoclasts, possibly through the utilization of current medications, could present a novel approach in managing lower back pain.